Skip to main content
. Author manuscript; available in PMC: 2024 Aug 15.
Published in final edited form as: Neuropharmacology. 2023 Apr 25;234:109545. doi: 10.1016/j.neuropharm.2023.109545

Figure 4. Inhibition of β ARs in aINS did not affect AOD or CLAD.

Figure 4.

(A,B) Intra-aINS administration of propranolol (0.5, 2, 5, or 10μg) had no impact on alcohol intake. (C) Administration of β1 ARs antagonist betaxolol (307ng) into aINS had limited effects on CLAD (see Results). *,** p<0.05, p<0.01 for treatment or drinking condition effects, from two-way ANOVA.